Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma

被引:23
作者
Castagna, MG
Pinchera, A
Marsili, A
Giannetti, M
Molinaro, E
Fierabracci, P
Grasso, L
Pacini, F
Santini, F
Elisei, R [1 ]
机构
[1] Univ Pisa, Dept Endocrinol & Metab, I-56100 Pisa, Italy
[2] Univ Siena, Dept Internal Med, I-53100 Siena, Italy
[3] Univ Siena, Dept Endocrinol & Metab, I-53100 Siena, Italy
[4] Univ Siena, Dept Biochem, I-53100 Siena, Italy
[5] Univ Pisa, AmbiSEN Ctr, High Technol Ctr Study Environm Damage Endocrine, I-56124 Pisa, Italy
关键词
D O I
10.1210/jc.2005-0534
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In this study, we evaluated the influence of height, weight, body mass index (BMI), body surface area, and body composition [total lean body mass (LBM) and fat body mass] on serum peak TSH levels obtained after recombinant human (rh) TSH. Furthermore, to verify whether the serum peak TSH influenced the efficacy of radioiodine (I-131), we compared the rate of thyroid remnant ablation according to the patients' BMI. Patients: We studied 105 patients with differentiated thyroid carcinoma who underwent rhTSH stimulation test. Serum TSH measurements were performed before and 24, 48, and 72 h after rhTSH administration. We also compared the rate of thyroid remnant ablation among 70 differentiated thyroid carcinoma patients with different BMI. Results: The serum peak TSH after rhTSH was significantly lower in overweight and obese subjects compared with normal-weight subjects (92.1 +/- 41.8, 82.4 +/- 24.2, and 112.7 +/- 46.3 mu U/ml, respectively; P = 0.01) and in males compared with females (74.6 +/- 22.3 and 105.0 +/- 43.0 mu U/ml, respectively; P = 0.0002). By univariate analysis, serum peak TSH was negatively related to weight, height, body surface area, BMI, LBM, and fat body mass, but only LBM was independently associated with serum peak TSH levels. Although it was confirmed that overweight and obese patients had a lower serum peak TSH, the rate of ablation did not differ among normal-weight, overweight, and obese patients. Conclusions: With this study we demonstrated that LBM is the only parameter independently associated with serum peak TSH after rhTSH administration. However, the serum peak TSH does not influence the rate of I-131 remnant ablation.
引用
收藏
页码:4047 / 4050
页数:4
相关论文
共 20 条
[1]   ABLATION OF REMAINING FUNCTIONING THYROID LOBE WITH RADIOIODINE AFTER HEMITHYROIDECTOMY FOR CARCINOMA [J].
ARAD, E ;
OMARA, RE ;
WILSON, GA .
CLINICAL NUCLEAR MEDICINE, 1993, 18 (08) :662-663
[2]   Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation [J].
Barbaro, D ;
Boni, G ;
Meucci, G ;
Simi, U ;
Lapi, P ;
Orsini, P ;
Pasquini, C ;
Piazza, F ;
Caciagli, M ;
Mariani, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4110-4115
[3]   Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy [J].
de Keizer, B ;
Brans, B ;
Hoekstra, A ;
Zelissen, PMJ ;
Koppeschaar, HPF ;
Lips, CJM ;
Rijk, PP ;
Dierckx, RA ;
Klerk, JMH .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (03) :367-373
[4]   A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer [J].
Haugen, BR ;
Pacini, F ;
Reiners, C ;
Schlumberger, M ;
Ladenson, PW ;
Sherman, SI ;
Cooper, DS ;
Graham, KE ;
Braverman, LE ;
Skarulis, MC ;
Davies, TF ;
DeGroot, LJ ;
Mazzaferri, EL ;
Daniels, GH ;
Ross, DS ;
Luster, M ;
Samuels, MH ;
Becker, DV ;
Maxon, HR ;
Cavalieri, RR ;
Spencer, CA ;
McEllin, K ;
Weintraub, BD ;
Ridgway, EC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :3877-3885
[5]   Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma [J].
Ladenson, PW ;
Braverman, LE ;
Mazzaferri, EL ;
BruckerDavis, F ;
Cooper, DS ;
Garber, JR ;
Wondisford, FE ;
Davies, TF ;
DeGroot, LJ ;
Daniels, GH ;
Ross, DS ;
Weintraub, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :888-896
[6]   Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH [J].
Lippi, F ;
Capezzone, M ;
Angelini, F ;
Taddei, D ;
Molinaro, E ;
Pinchera, A ;
Pacini, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 144 (01) :5-11
[7]   RADIOIODINE ABLATION OF RESIDUAL TISSUE IN THYROID-CANCER - RELATIONSHIP BETWEEN ADMINISTERED ACTIVITY, NECK UPTAKE AND OUTCOME [J].
LOGUE, JP ;
TSANG, RW ;
BRIERLEY, JD ;
SIMPSON, WJ .
BRITISH JOURNAL OF RADIOLOGY, 1994, 67 (803) :1127-1131
[8]   Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma [J].
Luster, M ;
Lassmann, M ;
Haenscheid, H ;
Michalowski, U ;
Incerti, C ;
Reiners, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3640-3645
[9]   A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma [J].
Mazzaferri, EL ;
Robbins, RJ ;
Spencer, CA ;
Braverman, LE ;
Pacini, F ;
Wartofsky, L ;
Haugen, BR ;
Sherman, SI ;
Cooper, DS ;
Braunstein, GD ;
Lee, S ;
Davies, TF ;
Arafah, BM ;
Ladenson, PW ;
Pinchera, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04) :1433-1441
[10]   LEAN BODY-MASS AS A PREDICTOR OF DRUG-DOSAGE - IMPLICATIONS FOR DRUG-THERAPY [J].
MORGAN, DJ ;
BRAY, KM .
CLINICAL PHARMACOKINETICS, 1994, 26 (04) :292-307